Compare Abeona Therapeutics Inc (ABEO) vs Trade Desk Inc (TTD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Trade Desk Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Trade Desk Inc trades at $19.05 (market cap $9.02B). The key difference: Trade Desk Inc is far larger — about 24.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TTD | |
|---|---|---|
Market Cap | $373.32M | $9.02B |
Sector | Health | Technology |
52-Week High | $7.23 | $89.76 |
52-Week Low | $4.17 | $17.33 |
Enterprise Value | $228.22M | $8.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
The Trade Desk (TTD) trades at $19.18, up 0.42% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though Q1 2026 earnings missed expectations. Revenue growth has been consistent, reaching $2.9B in 2025, while analyst sentiment remains divided with a $25.46 consensus target representing 33% upside potential.
TTD presents a compelling value opportunity with reasonable valuations (P/E 21.94, P/S 3.17) and strong cash flow generation, but faces near-term headwinds from recent earnings miss and competitive pressures in digital advertising. The stock's 86% decline from 2024 highs creates potential for recovery if execution improves, though investor caution is warranted given mixed analyst ratings and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
